期刊文献+

MIP-3α、CCR6表达预测小细胞肺癌患者胸腔镜肺癌根治术后复发转移的价值 被引量:3

The Value of MIP-3 and CCR6 Expression in Predicting Recurrence and Metastasis of Small Cell Lung Cancer after Thoracoscopic Radical Resection
下载PDF
导出
摘要 目的探讨小细胞肺癌(small cell lung cancer,SCLC)患者巨噬细胞炎性蛋白-3α(MIP-3α)、趋化因子C-C-基元受体6(CCR6)表达在预测胸腔镜肺癌根治术后复发转移中的临床价值。方法选取SCLC患者160例,术后随访2 a,根据术后是否发生复发转移分为转移组(n=70)和非转移组(n=90)。采用免疫化学染色检测MIP-3α、CCR6的表达;采用实时荧光定量PCR检测MIP-3α、CCR6 mRNA的表达,采用蛋白质印迹法检测MIP-3α、CCR6蛋白的表达。结果转移组MIP-3α、CCR6 mRNA分别为0.88±0.12、0.64±0.10,蛋白表达水平分别为3.92±0.13、2.87±0.35;非转移组MIP-3α、CCR6 mRNA分别为0.48±0.09、0.41±0.05,蛋白表达水平分别为1.00±0.00、1.01±0.00,转移组MIP-3α、CCR6 mRNA及蛋白表达水平高于非转移组,差异有统计学意义(P<0.05)。结论MIP-3α、CCR6在经胸腔镜肺癌根治术SCLC患者术后复发转移组织中高度表达,MIP-3α、CCR6可为SCLC的临床治疗提供参考。 Objective To explore the clinical value of MIP-3αand CCR6 expression in predicting the recurrence and metastasis of patients with small cell lung cancer(SCLC).Methods 160 patients with SCLC were selected.Follow-up for 2 years,the patients were divided into observation group(n=70)and control group(n=90)according to whether recurrence and metastasis.The expression of MIP-3αand CCR6 was detected by immunochemical staining,MIP-3αand CCR6 mRNA by real-time fluorescence quantitative PCR,MIP-3αand CCR6 protein by western blotting.Results In the observation group,MIP-3αand CCR6 mRNA were 0.88±0.12,0.64±0.10 and protein were 3.92±0.13 and 2.87±0.35,respectively;in the control group,MIP-3αand CCR6 mRNA were 0.48±0.09 and 0.41±0.05 and protein were 1.00±0.00 and 1.01±0.00.The expression of MIP-3αand CCR6 in the observation group was significantly higher than that in the control group,the difference between the two groups has statistical significance(P<0.05).Conclusion MIP-3 and CCR6 are highly expressed in recurrent and metastatic tissues of SCLC patients undergoing radical thoracoscopic surgery,and MIP-3αand CCR6 can provide references for the clinical treatment of SCLC.
作者 陈海全 李晓燕 马治欣 CHEN Haiquan;LI Xiaoyan;MA Zhixin(Department of Cardiothoracic Surgery, Pingdingshan The Second People’s Hospital, Pingdingshan Henan 467000,China)
出处 《河南医学高等专科学校学报》 2021年第1期23-27,共5页 Journal of Henan Medical College
关键词 小细胞肺癌 巨噬细胞炎性蛋白-3α 趋化因子C-C-基元受体6 复发转移 small cell lung cancer MIP-3 CCR6 thoracoscopic radical resection
  • 相关文献

参考文献6

二级参考文献58

  • 1李青,刘殿武,肖永红,刘辉,何海艳.不同剂量不同载体不同途径的肝再生增强因子重组质粒抗大鼠肝纤维化疗效比较[J].第三军医大学学报,2006,28(18):1833-1836. 被引量:5
  • 2Blanchazd P, Le Pechoux C. Prophylactic cranial irradiation in lung cancer[J]. Curr Opin Oncol, 2010, 22(2):94-101.
  • 3Seute T, Leffers P, Ten VG, et al. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MILl) . Cancer, 2008, 11 (8) : 1827-1834.
  • 4Lekic M, Kovac V, Triller N, et al. Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting[}]. Radiol Oncol, 2012, 46(1):54-59.
  • 5Kalemkerian GP, Akerley W, Bogner P, et al. Small cell lung can-cer[J].J Nad Compr Canc Netw, 2010:253-270.
  • 6Groome PA, Bolejack V, GrowleyJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forth- coming (seventh) edition of the TNM classification of malignant tumours[J].J Thorac Oncol, 2007, 2(8):694-705.
  • 7Eisenhauer EA, Therasse P, BogaertsJ, et al. New response evalu- ation criteria in solid tumours: revised RECIST guideline (ver- sion 1.1)[J]. EurJ Cancer, 2009,45(2):228-247.
  • 8Manapov F, Klautke G, Fietkau R. Prevalence of brain metastases immediately before prophylactic cranial irradiation in limited disease small cell lung cancer patients with complete remission to chemo- radiotherapy: a single institution experience. J Thorac Oncol, 2008, 3 (6):652-655.
  • 9Manapov F, Klocking S, Niyazi M, et al. Primary tumor response to chemoradiotherapy in limited-disease small--cell lung cancer correlates with duration of brain--metastasis free survivalS. J Neurooncol, 2012, 109(2):309-314.
  • 10Gong L, Wang QI, Zhao L, et al. Factors affecting the risk of brain metastasis in small cell lung cancer with surgery: is prophy- lactic cranial irradiation necessary for stage I -II1 disease[J]? IntJ Radiat Oncol Biol Phys, 2013, 85(1):196-200.

共引文献25

同被引文献25

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部